cis-3,4-dimethylsuccinimide | 64833-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: cis-3,4-dimethylsuccinimide
• 英文别名: cis-3,4-dimethyl-pyrrolidine-2,5-dione；cis-3,4-Dimethyl-pyrrolidin-2,5-dion；cis-3,4-dimethylpyrrolidine-2,5-dione；cis-2,3-Dimethylsuccinimid；(3R,4S)-3,4-dimethylpyrrolidine-2,5-dione
• CAS: 64833-44-9
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: KKDOXQYWUITYNG-ZXZARUISSA-N

物化性质

• 沸点：
  261.1±9.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-3,4-dimethylsuccinimide 在 lithium aluminium tetrahydride 、 三氯化铝 作用下， 以 乙醚 为溶剂， 以0.5 g的产率得到吡咯烷,3,4-二甲基-,反-
  参考文献：
  名称：

  Bachechi, Fiorella; Cellai, Luciano; Sparapani, Roberto, Journal of Chemical Research, Miniprint, 1989, # 1, p. 158 - 176

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二甲基吡咯-2,5-二酮 在 乙醇 、 铂 作用下， 生成 cis-3,4-dimethylsuccinimide
  参考文献：
  名称：

  1：2-二羧酸。第二部分 非对映异构体αα'-二甲基琥珀酸及其衍生物。构象对稳定性的影响

  摘要：

  DOI：

  10.1039/jr9540003722

文献信息

• Chemo- and Diastereoselectivities in the Electrochemical Reduction of Maleimides
  作者：Kathryn Rix、Geoffrey H. Kelsall、Klaus Hellgardt、King Kuok Mimi Hii

  DOI：10.1002/cssc.201403184

  日期：2015.2

  The electrochemical cathodic reduction of cyclic imides (maleimides) to succinimides can be achieved chemoselectively in the presence of alkene, alkyne, and benzyl groups. The efficiency of the system was demonstrated by using a 3D electrode in a continuous flow reactor. The reduction of 3,4‐dimethylmaleimides to the corresponding succinimides proceeds with a 3:2 diastereomeric ratio, which is independent

  在烯烃，炔基和苄基的存在下，可以化学选择性地将环状酰亚胺（马来酰亚胺）电化学还原成琥珀酰亚胺。通过在连续流反应器中使用3D电极证明了系统的效率。将3,4-二甲基马来酰亚胺还原为相应的琥珀酰亚胺，其非对映异构体比例为3：2，这与氮取代基和电极表面积无关。通过使用DFT计算合理化了该过程的立体选择性，其中涉及通过双氢转移机制发生的半烯醇的酸催化互变异构。
• Aryloxy-Substituted Benzimidazole Derivatives
  申请人：Hashimoto Noriaki

  公开号：US20080125429A1

  公开（公告）日：2008-05-29

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R 1 and R 2 represent a hydrogen, etc.; R 3 represents a hydrogen atom, a halogen atom, etc.; R 4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R 5 and R 6 each represent a hydrogen atom, a lower alkyl group, etc.; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X 1 to X 4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及用于糖尿病的治疗和/或预防，或用于糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化等的治疗和/或预防，以及用于肥胖症的治疗和/或预防。本发明涉及一种化合物的公式(I)：[其中R1和R2分别表示氢等；R3表示氢原子、卤原子等；R4各自独立地表示氢原子、低级烷基等；Q表示碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自表示氢原子、低级烷基等；X1、X2、X3和X4各自独立地表示碳原子或氮原子；Z表示氧原子、硫原子或氮原子；Ar表示芳基或杂环芳基，可选择性地单取代至三取代于β取代基；环A表示一个含氮的5-或6成员杂芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（前提是X1至X4中至少有两个是碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，并且可用作糖尿病的治疗。
• Aryloxy-substituted benzimidazole derivatives
  申请人：MSD K.K.

  公开号：US07932394B2

  公开（公告）日：2011-04-26

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X1 to X4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及一种治疗和/或预防糖尿病，或一种治疗和/或预防糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化，以及进一步治疗和/或预防肥胖症的药物。本发明涉及公式(I)的化合物：[其中R1和R2代表氢等；R3代表氢原子、卤原子等；R4各自独立地代表氢原子、较低的烷基等；Q代表碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自代表氢原子、较低的烷基等；X1、X2、X3和X4各自独立地代表碳原子或氮原子；Z代表氧原子、硫原子或氮原子；Ar代表芳基或杂环芳基，可选择性地单取代至三取代于从取代基β选择的基团；环A代表一含有5-或6-成员的含氮杂环芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（但至少X1至X4中的两个为碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，可用于治疗糖尿病。
• ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：MSD K.K.

  公开号：EP1810969B1

  公开（公告）日：2013-08-07
• Bischoff; Voit, Chemische Berichte, 1890, vol. 23, p. 644
  作者：Bischoff、Voit

  DOI：——

  日期：——

表征谱图